✦ LIBER ✦

Phase II study of docetaxel (DOC) and carboplatin (CP) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)

✍ Scribed by van Putten, J.W.G; Slebos, D.J; Groen, H.J.M

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel and carboplatin combination as

✍ J.W.G. Van Putten; F.M. Wachters; H.J.M. Groen 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Phase I study of second-line chemotherap

✍ Mikio Oka; Minoru Fukuda; Seiji Nagashima; Masaaki Fukuda; Akitoshi Kinoshita; H 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 84 KB

P-526 Phase I/II study of GTI-2040 plus

✍ Leighl, N.; Laurie, S.; Knox, J.; Ellis, P.; Shepherd, F.; Burkes, R.; Pond, G.; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 286 KB

Second-line treatment with vinorelbine a

✍ Agelaki, Sophia; Bania, Helen; Kouroussis, Charalambos; Blazoyiannakis, George; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Second-line treatment with single-agent

✍ van Putten, J.W.G; Baas, P; Codrington, H; Kwa, H.B; Groen, H.J.M 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Phase I study of docetaxel (DTX) and car

✍ Sawada, M; Kubota, K; Ito, R; Watanabe, H; Akiyama, Y; Kusaba, H; Yamamoto, N; S 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 105 KB